Mumbai / New Delhi — A startling audit report submitted by Maharashtra Food and Drug Administration (FDA) Commissioner Tukaram Mundhe has exposed excessive trade markups on essential surgical consumables and medical devices in private hospitals.
What regulators call a glaring loophole in medical billing, patients experience as a silent drain on their savings during hospital stays.
Selling Patient Care at Astronomical Margins
The Maharashtra FDA market survey examined procurement invoices and patient billing across various healthcare facilities, exposing exorbitant price gaps between wholesale purchase costs and retail bills charged to hospitalized patients:
- Infusion Sets: Purchased by hospitals at ₹11, but billed to patients at ₹325 (a staggering 2,841% markup).
- Nebulizer Kits: Bought at ₹45, billed up to ₹652.
- Cannula Extensions: Procured at ₹22, billed at ₹424.
- HEPA Breathing Filters: Acquired at ₹50, priced at ₹473.
- Catheters: Bought at ₹29, priced at ₹310.
- Standard Syringes: Purchased at ₹6, billed at ₹57.
Trapped in the Hospital Room: The Vulnerability of Patients
In his report submitted to the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority (NPPA), Mundhe emphasized that initial wholesale purchase prices already fully cover manufacturing, development, distribution, marketing costs, and healthy profit margins.
However, hospitalized patients are uniquely vulnerable:
- Zero Bargaining Power: Patients cannot negotiate prices or step outside to purchase cheaper items from local pharmacies during treatment.
- Absorbing the Retail Price: With no alternative choices available in a hospital setting, patients have no option but to absorb the heavily inflated retail prices printed on their bills.
A Regulatory Grey Area: Devices vs. Essential Medicines
Under the Drug Price Control Order (DPCO) 2013, the NPPA enforces strict ceiling prices for essential formulations listed under Schedule I.
While surgical consumables are classified as medical devices, most of them remain excluded from this essential list. Because they are categorized as non-scheduled products:
- Their retail prices cannot legally increase by more than 10% in a single year.
- However, there is no direct cap on profit margins between the wholesale purchase rate and the final patient billing—allowing private healthcare facilities to legally exploit this grey area.
A Growing National Pushback
Maharashtra is not alone in highlighting the issue. Several other states—including Punjab, Rajasthan, and Tamil Nadu—have submitted similar representations before the central government, urging immediate regulatory intervention against excessive trade markups on medical consumables and devices within private healthcare systems.
The NPPA is currently cross-verifying internal company price lists and state procurement data to evaluate whether formal margin limits are necessary nationwide.
Recommendations for Reform
The Maharashtra FDA has put forward definitive recommendations to fix the loophole:
- Direct Price Control: Bring inpatient surgical consumables under direct price control regulations.
- Markup Caps: Establish statutory limits on the markups between wholesale costs and retail patient billing.
- Inter-Agency Review: Conduct a coordinated review between the Department of Pharmaceuticals, the NPPA, and state governments.
Bottom Line
The era of hidden, exorbitant markups on essential medical supplies has thrived on the helplessness of hospitalized patients. With regulatory bodies and state administrations stepping up pressure, the push for strict price caps on surgical consumables aims to ensure that healthcare remains about healing rather than capitalizing on vulnerability.
